Sign In
Buy CRBU
$2.00
-0.320 (-13.79%)
At Close: Jun 03, 2026
Wall Street Analysts Believe Caribou Biosciences, Inc. (CRBU) Could Rally 285.29%: Here's is How to Trade
11:16am, Wednesday, 06'th Dec 2023
The mean of analysts' price targets for Caribou Biosciences, Inc. (CRBU) points to a 285.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agree
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
08:30am, Monday, 04'th Dec 2023
Genomic medicine is predicted to become a multi-billion-dollar industry. Even so, this market will probably take years to mature, and risks abound as a result.
Caribou Biosciences: Upcoming CB-010 Data Could Send The Bears Packing
11:42pm, Sunday, 26'th Nov 2023
In July, Caribou Biosciences reported positive data from the Antler study of its CAR-T therapy, CB-010, and a $25M investment from PFE. Data from the dose expansion portion of the Antler study are exp
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip
05:40am, Tuesday, 10'th Oct 2023
Caribou Biosciences stock could rocket up more than 400%, according to the consensus price target from Wall Street analysts. Caribou's lead candidate is an off-the-shelf cellular cancer therapy for ly
1 Gene Editing Stock to Buy Now, and 1 to Sell
08:45am, Saturday, 23'rd Sep 2023
Caribou Biosciences has plenty of money for the next year or so, and great data. Editas Medicine is far behind the competition with its lead programs.
Caribou Biosciences to Participate in Upcoming Investor Conferences
04:00pm, Tuesday, 29'th Aug 2023
BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company's p
Is Caribou Biosciences (CRBU) Stock Outpacing Its Medical Peers This Year?
04:11pm, Tuesday, 15'th Aug 2023
Here is how Caribou Biosciences, Inc. (CRBU) and DexCom (DXCM) have performed compared to their sector so far this year.
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates
06:57pm, Tuesday, 08'th Aug 2023
Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.46 per share a year ago.
3 Reasons Why Caribou Biosciences Is a Screaming Buy in July and Beyond
08:30am, Friday, 28'th Jul 2023
Caribou's cell therapy programs are among the most advanced that exist. So far, they also appear to be relatively safe and quite effective.
This 1 Innovation Could Make These 2 Biotechs Soar by 2030
09:45am, Saturday, 22'nd Jul 2023
It's cumbersome and costly to manufacture complicated cell therapies. Caribou Biosciences and CRISPR Therapeutics have a better way of doing things.
Got $1,000? Buying Caribou Biosciences Stock Right Now Could Be a Brilliant Move in 5 Years
10:00am, Friday, 21'st Jul 2023
Caribou Biosciences just released promising data on its lead cancer therapy. It also just issued a bunch of new stock, improving its cash position.
2 Growth Stocks That Could Rocket 81% to 233% Higher, According to Wall Street
11:35am, Thursday, 20'th Jul 2023
The market has already risen sharply this year, but Wall Street analysts think these two stocks haven't received the attention they deserve. Caribou Biosciences is a clinical-stage drugmaker developin
2 Stocks I'm Buying on the Dip This Week
05:03pm, Monday, 17'th Jul 2023
Sudden and dramatic downturns in a company's share price can sometimes represent an incredible buying opportunity. Caribou Biosciences and AT&T may fall into this bucket after losing a significant chu
Caribou Biosciences: Positive CB-010 Data Leads To First Half 2024 Catalyst
05:11am, Monday, 17'th Jul 2023
Caribou Biosciences' results from the dose expansion portion of the phase 1 ANTLER study, using CB-010 for the treatment of patients with relapsed/refractory second-line LBCL patients, are expected in
Caribou Biosciences offers more stock, and shares fall
04:48pm, Thursday, 13'th Jul 2023
Shares of Caribou Biosciences Inc. CRBU, +4.90% tumbled 9.7% after hours on Thursday after the biopharma company said it had begun a $100 million share offering. The company, which focuses on genome e
